经典先天性肾上腺增生症成人患者启用Crinecerfont后糖皮质激素减量的实用框架
Crinecerfont是一种促肾上腺皮质激素释放因子1型受体拮抗剂,获FDA批准作为经典先天性肾上腺增生症患者生理性糖皮质激素治疗的辅助用药,通过降低促肾上腺皮质激素控制雄激素过多,从而允许减少糖皮质激素剂量。本文由11名内分泌专家组成的小组制定框架,提出糖皮质激素减量应个体化、逐渐进行,并调整至维持雄激素达标所需的最低水平。
要点
- 糖皮质激素减量应个体化,基于患者治疗目标、皮质醇需求、生活方式偏好和临床经验设定目标。
- 糖皮质激素应逐渐减量,以尽量减少糖皮质激素撤药症状或肾上腺功能不全的风险。
- 减量期间可考虑将长效糖皮质激素转换为短效制剂,优化剂量分布以模拟生理昼夜节律,并简化给药方案。
核心结论
- 对于使用Crinecerfont的经典先天性肾上腺增生症成人患者,糖皮质激素减量应个体化并逐渐进行,调整至维持雄激素达标所需的最低剂量,且不低于皮质醇替代所需水平。
研究设计与样本
- 由11名经验丰富的内分泌专家组成的小组讨论糖皮质激素减量策略和考虑因素,并制定减量算法。
主要发现
- 糖皮质激素减量应基于患者治疗目标、皮质醇需求、生活方式偏好和临床经验个体化设定临床参数、雄激素和糖皮质激素方案的目标。
- 糖皮质激素应逐渐减量以尽量减少糖皮质激素撤药症状或肾上腺功能不全的风险。
- 糖皮质激素剂量应调整至维持雄激素达标所需的最低水平,且不低于皮质醇替代所需剂量。
关键数值与推荐
- 糖皮质激素减量期间的实际考虑包括将长效糖皮质激素转换为短效制剂(如从地塞米松转换为氢化可的松)。
- 优化剂量分布以模拟正常昼夜皮质醇暴露。
- 合并或消除给药次数以提高依从性。
临床怎么用
- 在成人经典先天性肾上腺增生症患者中启用Crinecerfont后,可参考本框架逐步减少超生理剂量的糖皮质激素,同时监测雄激素和皮质醇需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, is FDA-approved as an adjunct to the physiologic glucocorticoid (GC) required to treat the underlying adrenal insufficiency in patients (≥4 years old) with classic congenital adrenal hyperplasia (CAH). By reducing elevated adrenocorticotropic hormone, crinecerfont controls excess adrenal androgens, thereby enabling lower GC doses. However, there are no published recommendations for how to reduce supraphysiologic GC doses after initiating crinecerfont. This manuscript aims to provide a framework developed by experienced endocrinologists for reducing supraphysiologic GC doses in patients taking crinecerfont. EVIDENCE ACQUISITION: An experienced panel of 11 endocrinologists discussed strategies and considerations when reducing GC doses and developed an algorithm to guide GC dose reductions after introducing crinecerfont in adults with CAH. EVIDENCE SYNTHESIS: Approaches to GC reduction should be individualized based on the patient's therapeutic goals, cortisol needs, lifestyle preferences, and the clinician's experience to set appropriate targets for clinical parameters, androgens, and GC dose regimen. In general, GC doses should be reduced gradually to minimize the risks of developing symptoms of GC withdrawal or adrenal insufficiency. GC doses should be adjusted to the lowest level needed to maintain androgens at goal, without reducing below what is needed for cortisol replacement. Practical considerations during GC dose reduction include switching from longer- to shorter-acting GCs (eg, from dexamethasone to hydrocortisone), optimizing dose distribution to mimic normal circadian cortisol exposure, and consolidating or eliminating doses to improve adherence. CONCLUSION: This framework for reducing supraphysiologic GC doses in adult patients taking crinecerfont may become increasingly relevant as treatment of CAH shifts toward physiologic GC replacement with adjunctive control of adrenal androgens.
引用
- Hamidi O, Auchus RJ, Correa R, et al. Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives. J Clin Endocrinol Metab. 2026. PMID: 41921547. doi:10.1210/clinem/dgag147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。